Rainier Acquisition Corporation said its underwriter fully exercised the over-allotment option for its initial public offering, adding 1,125,000 units at $10.00 each. The September 2, 2026 closing increased total units sold to 8,625,000 and aggregate gross proceeds to $86,250,000 before underwriting discounts and offering expenses, with the same amount held in the company’s trust account. Each unit comprises one Class A ordinary share and one-quarter of a redeemable warrant, while each whole warrant allows the holder to buy one Class A ordinary share for $11.50. The units began trading on the Nasdaq Capital Market on August 27 under RNAQU; the shares and warrants are expected to trade separately under RNAQ and RNAQW. The special purpose acquisition company is seeking a business combination, with an intended focus on global life sciences, including therapeutics, diagnostics, genomics, precision medicine, life science tools, research services and biomanufacturing, although its search is not limited by industry or geography.